Roche’s Rituximab Gains Two New Indications In The EU
This article was originally published in The Pink Sheet Daily
Executive Summary
MabThera, marketed by Genentech/Biogen Idec in the U.S. as Rituxan, is now approved in Europe for maintenance NHL and RA.